Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- Chuikyo Payer Rep Wants to Cut into Cost-Based Method, Adjustment Rate, Off-Year Revision in FY2022 Reform, Eyes Special Rules for Aducanumab
September 27, 2021
- Teva Takeda CEO Named Chairman of Established Drugs’ Group
September 24, 2021
- JPMA Chief Opposes Macroeconomic Indexing, Says Drugs Should Drive Economic Growth
September 22, 2021
- FPMAJ Conducting Survey on Efforts for Stable Supplies of Ethical Drugs; Response Deadline Sept. 30
September 21, 2021
- JPMA Suspends Ono’s Membership over Onoact Bribery Case
September 17, 2021
- Bills Exceeding 10 Million Yen Monthly Increase 60%, SMA Dominates Top 7: Payer Report
September 17, 2021
- JMA Think Tank Sees Problems with Proposals to Revise Health Coverage for Drugs
September 15, 2021
- Generic Trade Group Sets Out 4 Pledges on Quality, Stable Supply
September 15, 2021
- FPMAJ Vows to Work towards Achieving New Pharma Industry Vision
September 15, 2021
- Established Drugs’ Group Boots Up with 6 Firms Plus One Organization
September 14, 2021
- PhRMA Hails Japan's New Pharma Industry Vision
September 14, 2021
- JMA Think Tank Urges Discussions to Prep for Aducanumab Approval
September 8, 2021
- Plaintiffs of HPV Vaccine Suits Urge MHLW Not to Reinstate Recommendation
September 6, 2021
- EFPIA Japan Issues Viewpoint on Cost Effectiveness Assessment System
August 31, 2021
- EFPIA Japan Appoints Sanofi’s Takahiko Iwaya as New Chair
August 25, 2021
- COVID-19 Oxygen Stations Should Provide Corticosteroids and Anticoagulants Too: JMA Executive
August 24, 2021
- New Established Medicines’ Association to Discuss Info Transfer Rules for LLP Withdrawals
August 20, 2021
- New Established Drugs’ Group Places Top Priority on Stable Generic Supply; Research-Driven and Foreign Firms to Join
August 20, 2021
- Generic Use Rate at 79.4% in FY2020, Up 2.5 Points: JGA
August 3, 2021
- New Industry Czar Vows to Balance Interests of Innovative Pharma, Gx Businesses as Budget Debate Creates Divide
July 30, 2021
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…